23 февр. 2024 г. · Vertex Pharmaceuticals ' gene therapy Casgevy lists for $2.2 million, while Bluebird Bio 's treatment Lyfgenia lists for $3.1 million.

15 дек. 2023 г. · Using CRISPR technology, Casgevy comes in at a much cheaper price of $2.2 million compared to Lyfgenia's $3.1 million price tag.

14 мар. 2024 г. · The two gene therapy treatments for sickle cell disease recently approved by the FDA, called Casgevy and Lyfgenia, cost $2.2 million and $3.1 ...

8 дек. 2023 г. · Bluebird is pricing Lyfgenia at a wholesale acquisition cost of $3.1 million, about 40% higher than the $2.2 million list price Vertex has ...

21 дек. 2023 г. · The list price for Lyfgenia is set at $3.1 million, joining other gene therapies as among the most expensive treatments worldwide. Casgevy will ...

8 дек. 2023 г. · bluebird has set the wholesale acquisition cost of LYFGENIA in the U.S. at $3.1M in recognition of the value the therapy may deliver through ...

6 мая 2024 г. · Both therapies are among the most expensive drugs on the market. Bluebird set Lyfgenia's price at $3.1 million, while Vertex Pharmaceuticals, ...

12 дек. 2023 г. · Cost is one factor behind this reality: Casgevy will cost $2.2 million per treatment, and Lyfgenia $3.1 million. But the challenge of access is ...

8 дек. 2023 г. · Bluebird bio, which also received FDA clearance for its genetic medicine Lyfgenia the same day, chose a higher price of $3.1 million.

9 дек. 2023 г. · Bluebird set the wholesale price of Lyfgenia at $3.1 million. The Institute for Clinical and Economic Review, which advises drugmakers and ...